Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

The global dermatology market is set to experience strong growth from $20 billion in 2015 to $33.7 billion by 2022.

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Read Report Brief @ http://www.marketintelreports.com/report/gbihc390mr/global-dermatology-market-to-2022--innovative-pipeline-and-increasing-uptake-of-biologics-to-diversify-treatment-options-and-drive-strong-growth

According to the company’s report, the rise will occur in spite of the patent expiries of many marketed monoclonal Antibodies (mAbs), which are unlikely to have a significant impact due to the practical and regulatory barriers faced by biosimilars. Growth will be driven by a strong late-stage pipeline, which includes several highly valuable targeted therapies, such as dupilumab, AN-2729, AMG-827 and ixekizumab.

Jennifer Goossens, commented: “There are currently a number of promising biologics in the pipeline for major skin disorders, including atopic dermatitis, acne vulgaris and rosacea, with 17 biologics in Phase III of development. This sizeable number suggests that they could have a considerable impact on treatment algorithms in the dermatology therapy area over the forecast period.”

In terms of specific products, Regeneron/Sanofi’s dupilumab is the leading candidate to bring about a paradigm shift in the treatment moderate-to-severe atopic dermatitis. At the same time, the use of older systemic immunosuppressants in dermatology is likely to decrease once biologics for other key indications besides psoriasis enter the market from 2016.
However, the dermatology space is not likely to experience major shifts in terms of its big players by 2022. Goossens added: “Key market players, namely Johnson & Johnson, AbbVie, Amgen, Novartis, and Roche, are expected to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries – especially AbbVie’s Humira and Johnson & Johnson’s Remicade – will affect these companies directly.”

Download Sample Brochure of Report Here @ http://www.marketintelreports.com/pdfdownload.php?id=gbihc390mr

Key Questions Answered in the report:
The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.
Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
• Which molecular targets are most prominent within the pipeline?
• How do the key indications differ in terms of molecule type?
• How does the composition of the pipeline compare with that of the existing market?
• What mechanisms of action are most common for pipeline drugs?
• Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.
• Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
• What CAGR will these companies register in the forecast period?

About us:
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

Contact us:
Sales Manager
Mayur S.
2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808
United States
www.marketintelreports.com

This release was published on openPR.